Thymopentin

What is Thymopentin?

Thymopentin (TP-5, sequence Arg-Lys-Asp-Val-Tyr) is a 5-residue active fragment of thymopoietin, the 49-residue thymic peptide characterized in the 1970s as part of Allan Goldstein's broader thymosin and thymic-peptide research program at Albert Einstein College of Medicine and George Washington University. The TP-5 sequence corresponds to residues 32-36 of thymopoietin and was shown to retain the immunomodulatory activity of the parent peptide in pituitary and thymocyte assays — making it a tractable synthetic active counterpart to the larger natural-extract preparations. The 1979 Tischio paper in International Journal of Peptide and Protein Research (PMID 395119) characterized TP-5's plasma half-life as short (a key practical limitation), and subsequent decades of work explored TP-5's effects on T-cell maturation and immune function across various disease contexts. Thymopentin reached limited clinical use in some markets (sold as Timunox by Cilag/Janssen) for chronic immune dysfunction indications including atopic dermatitis, rheumatoid arthritis, and immunodeficiency states. The Singh 1998 Immunology Research paper (PMID 9638477) consolidated thymopentin and the related splenopentin as immunomodulators, framing the pentapeptide approach within the broader thymic-peptide therapy landscape. The Bräuer 1993 Agents and Actions paper (PMID 8317333) extended the work to thymic and splenic peptide effects in antigen-induced arthritis. The translational adoption has been limited by the short plasma half-life requiring frequent dosing, the modest efficacy magnitude relative to the emerging biologic immunotherapy class, and the absence of FDA approval. Thymopentin is no longer in active commercial development in major Western markets and is not FDA-approved for any indication, but the molecule retains research interest as a small immunomodulatory peptide with documented thymic-pathway pharmacology.

What Thymopentin Is Investigated For

Thymopentin is a research-and-historical-clinical-agent topic, not a contemporary mainstream therapy. The 5-residue Arg-Lys-Asp-Val-Tyr peptide retains the immunomodulatory activity of the parent thymopoietin (the 49-residue thymic peptide characterized by Allan Goldstein's research program). The historical clinical translation included limited use in atopic dermatitis, rheumatoid arthritis, and chronic immune dysfunction in some European and Asian markets (notably as Timunox), but did not reach FDA approval and has been substantially superseded by the modern biologic immunotherapy class. The 1998 Singh Immunology Research review (PMID 9638477) is the standard reference framing thymopentin and splenopentin as immunomodulators within the broader thymic-peptide therapy concept. The short plasma half-life (Tischio 1979 PMID 395119) was a practical limitation requiring frequent dosing — typically subcutaneous administration multiple times per week. As of 2026, thymopentin is no longer in active commercial development in major Western markets and is not FDA-approved for any indication. The molecule is sold through some research-channel sources for laboratory use and remains conceptually relevant within the Thymic Peptides family pillar discussion.

How It Works

Thymopentin is a tiny 5-amino-acid piece of a thymus protein that helps T-cells mature properly. It was discovered in the 1970s and used as a drug in some countries (sold as Timunox) for things like atopic dermatitis and rheumatoid arthritis, but it never got FDA approval in the U.S. The problem is that the peptide breaks down very quickly in the body, so you have to inject it several times a week, and the modern biologic drugs that target specific immune molecules (TNF inhibitors, IL-6 inhibitors, dupilumab, etc.) work much better for the same conditions. Thymopentin is mostly a historical peptide now — interesting biology, limited current clinical use.

Thymopentin (TP-5) is a 5-residue peptide (Arg-Lys-Asp-Val-Tyr) corresponding to residues 32-36 of the 49-residue thymopoietin precursor. The discovery framework came from Allan Goldstein's broader thymic-peptide research program at Albert Einstein College of Medicine and later George Washington University in the 1970s. Thymopoietin itself was characterized as a thymic peptide with effects on T-cell maturation distinct from thymosin alpha-1 and other thymic peptides — and the TP-5 active fragment was shown to retain the principal immunomodulatory activity in pituitary, thymocyte, and immune cell assays. The 1979 Tischio paper in International Journal of Peptide and Protein Research (PMID 395119) characterized TP-5's short plasma half-life — a key practical limitation that has constrained therapeutic translation throughout the molecule's commercial history. The immunomodulatory mechanism includes effects on T-cell maturation, modulation of T-cell function in immune dysregulation contexts, and effects on the cytokine production profile of activated immune cells. The mechanism is broad-spectrum rather than specifically targeted, contrasting with the modern biologic immunotherapy class that targets specific cytokines or receptors. The Singh 1998 Immunology Research review (PMID 9638477) consolidated thymopentin and the related splenopentin as immunomodulators within the broader thymic-and-splenic peptide therapy concept. The Bräuer 1993 Agents and Actions paper (PMID 8317333) extended the work to thymic and splenic peptide effects in antigen-induced arthritis. The clinical translation of thymopentin reached limited commercial use in some markets through Cilag/Janssen's Timunox preparation, with applications in chronic immune dysfunction including atopic dermatitis, rheumatoid arthritis, and immunodeficiency states. The dosing regimen (typically 50 mg subcutaneously three times weekly) reflected the short plasma half-life and the broad-spectrum immunomodulator mechanism. The clinical efficacy was modest by modern biologic-immunotherapy standards, and the FDA approval was never obtained. The Menzaghi 1996 Physiology and Behavior paper (PMID 8840897) characterized IRI-514, a synthetic peptide analog of thymopentin, in stress-response models — extending the molecule's research footprint beyond pure immunomodulation into broader behavioral and stress-response biology.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Thymopentin:

• 01Modern controlled clinical trials of thymopentin against current standard-of-care biologic immunotherapy in atopic dermatitis, rheumatoid arthritis, or other immune-dysfunction indications
• 02Characterization of any niche clinical role thymopentin might retain in the modern targeted-immunotherapy landscape
• 03Long-term safety profile of contemporary thymopentin administration if any clinical pathway were revisited

Forms & Administration

Thymopentin in historical clinical use was administered as subcutaneous injection at 50 mg three times weekly under the Timunox brand. The molecule is no longer in active commercial development in major Western markets and is not FDA-approved. Synthetic thymopentin is sold by some research-chemical suppliers for laboratory use.

Common Questions

Who Thymopentin Is NOT For

Drug & Supplement Interactions

There is no validated contemporary drug-interaction profile for thymopentin. Theoretical interactions follow from the broad-spectrum immunomodulatory mechanism. Concurrent use with immunosuppressants, modern biologic immunotherapy, or other immune-modulating agents is uncharacterized and could produce unpredictable additive or opposing effects.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions